Sarepta Therapeutics (SRPT) 30-day option implied volatility at 44
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Sarepta (SRPT) sinks 20% as surprise FDA AdComm for SRP-9001 adds risk
March 17, 2023 6:52 AM EDTShares of Sarepta Therapeutics (NASDAQ: SRPT) fell 20% in pre-open trading Friday after the company announced a surprise FDA AdComm for SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy. The news comes just a few weeks after management indicated that there would be no AdComm.
While the news adds a layer of risk, most analysts still expected FDA approval at the May 29th PDUFA date.
"FDAs decision to hold a public advisory committee meeting on the SRP 9001 BLA is a change from the communicated... More
